Investment
Features
FeesSafety
Academy
More
Pluang+

Tokenized stocks on Solana hit $553M daily volume, dominating on-chain equity trading.

Protocol Fundamentals
25 Jun 2026
Crypto Briefing
View Source
Bullish
Tokenized stocks on Solana hit $553M daily volume, dominating on-chain equity trading.

Tokenized stocks on the Solana blockchain reached a new daily trading volume record of $553 million on June 24, 2026, capturing nearly all global on-chain equity trading with about 95-98% market share. This surge is driven by platforms like Backpack, offering fractional shares of private companies such as SpaceX, and Sunrise DeFi, enabling 24/7 trading and DeFi integration. Solana's low fees and high speed make it ideal for retail investors trading small amounts, expanding the user base beyond whales. While regulatory and concentration risks remain, the $10 billion cumulative volume milestone signals tokenized equities are becoming a mainstream alternative market, with Solana leading this shift.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
56 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

A 4chan post from December 2023 accurately predicted Bitcoin's all-time high of around $126,000 on October 6, 2025, based on a 364-day market cycle pattern. Following the peak, Bitcoin dropped about 52% by mid-2026 but has since recovered to roughly ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App